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ABSTRACT 
  
  
Genetic engineering is currently dominated by CRISPR/Cas9 technology, promising precise 
multipurpose genome editing. The 2016 WPI iGEM team investigated the potential of adapting 
this technology to direct single-base editing of mRNA by linking deactivated Cas9 to the C-to-U 
RNA editor enzyme APOBEC1. We pursued the re-cloning and characterization of the 
dCas9/APOBEC fusion to identify and eliminate problems related to expression and toxicity. 
Ultimately, this adapted CRISPR/Cas9 system could provide an advantageous method of editing, 
particularly for therapeutics. 
  
 
 
  
INTRODUCTION 
  
  
The natural CRISPR/Cas9 system employs a bacterial adaptive immune response in which 
clustered regularly-interspaced short palindromic repeats (CRISPRs) are recognized by the 
nuclease Cas9 and cleaved for the purpose of editing the gene in an effort to ensure organism 
survival. This system has been specially adapted for the use of targeting virtually any position in 
the genome by guiding the Cas9 to recognize specific sites of double-stranded DNA (dsDNA), 
usually via engineered single-guideRNAs (sgRNAs) (Ran et al. 2013). A simple diagram of the 
mechanism of CRISPR/Cas9 technology is below: 
 
 
Figure 1: A Diagram of CRISPR/Cas9 Editing Technology (Lewis 2015) 
 
Because of its natural derivation and high efficiency, the CRISPR/Cas9 system has quickly 
developed into a highly-regarded gene editing technology, through both recombination-based 
and single-base editing. In recombination-based editing, Cas9 cuts the dsDNA at a target locus, 
where the DNA is edited in the desired way (i.e. gene edits, knockouts), and the cell undergoes 
either non-homologous end joining (NHEJ) or homology-directed repair (HDR), although 
typically NHEJ (Ran et al. 2013). In single-base editing, the CRISPR/Cas9 system foregoes 
double-stranded DNA cleavage but retains editing power through an attached DNA-editing 
deaminase enzyme called APOBEC, which targets specific bases to be changed to a different 
nucleotide, such as a C→U substitution (Komor et al. 2016). 
  
While CRISPR technology has become a rather valuable tool in modern molecular biology, the 
current system is not without its issues, both technically and ethically. Biologically, Cas9’s 
ability to cut so efficiently at specific sequences on the genomic level is what makes it such a 
useful tool; however, sequences similar to the target sequence are often also cut, resulting in 
unpredictable and irreversible off-target effects (Harrison et al. 2014). After the initial cut by 
Cas9, cells routinely use the NHEJ repair pathway to repair the genomic DNA. This repair 
mechanism is often inaccurate and leads to frequent insertions, deletions, and changes of 
nucleotides. These indel and single-point mutations are unpredictable and irreversible, with the 
potential to yield drastic, undesirable results (Harrison et al. 2014). Lastly, the extent of complex 
post-transcriptional modifications and splicing variation allows for a myriad of uncontrollable 
outcomes, due to the nature of editing primary genetic material. Our project was motivated 
partially due to these technical concerns, and partially due to the share of ethical and safety 
concerns that naturally come from genetic engineering. 
  
In response to these concerns, one adaptation to the current CRISPR/Cas9 gene-editing system 
has been to target RNA instead of DNA. It has been shown that CRISPR/Cas9 can in fact be 
programmed to recognize single-stranded RNA (ssRNA) while avoiding the corresponding DNA 
sequences, and further cleave the targeted RNA in this manner (O’Connell et al. 2014). 
Furthermore, the CRISPR/Cas9 system has been demonstrated to be useful for live RNA 
tracking in vivo (Nelles et al. 2016). Finally, very recent progress by the Huang group has 
addressed the need to develop an mRNA-based CRISPR tool; their work validated the possibility 
of efficient targeting of cellular mRNA by an enzymatically dead Cas9, without affecting its 
corresponding DNA segments (2016). 
  
Therefore, understanding the technical and ethical issues presented by the common system of 
DNA-targeting CRISPR/Cas9, having studied the precedent of RNA targeting with 
CRISPR/Cas9, and inspired by the foundational work of the 2016 Worcester Polytechnic 
Institute (WPI) iGEM team in this field, we developed an adapted CRISPR/Cas9 system that also 
targets mRNA (WPI_Worcester, 2016). Another significant change from the current technology 
is that it utilizes the DNA/RNA editing enzyme APOBEC to cause specific single-base edits. 
  
 
Figure 2: A Diagram of Targeted mRNA Editing by dCas9/APOBEC 
 
In this way, we can make very precise adjustments to the mRNA of a desired organism, 
regulating its related protein levels, without editing a single nucleotide of DNA. Additionally, the 
application of this tool would be a temporary therapy; in the case of any unforeseen error or 
mutation, the same regulation could be easily reversed by stopping the editing of mRNA. We 
propose that this mRNA/CRISPR/Cas9-APOBEC system can be used for the same research and 
therapeutic purposes as the original CRISPR gene-editing technology, but with significantly 
reduced scientific and ethical risk, as well as increased accuracy. 
 
Our project continued the foundational work done by the 2016 WPI iGEM team in its efforts to 
develop this promising adapted CRISPR/Cas9 therapy. Herein, we describe our attempt to re-
clone the dCas9/APOBEC construct. We also describe our conclusion of the project with 
transfection trials of several constructs into mammalian cells.  
  
 MATERIALS & METHODS 
 
Preparation of pcDNA3.1+ 
We transformed 2 uL pcDNA3.1+ template vector DNA (provided by the WPI 2016 iGEM 
team) into 50 uL chilled, thawed competent DH5α e. coli cells. They were then incubated on ice 
for 30 minutes, heat shocked at 42°C for 1 minute, and incubated back on ice for 5 minutes. 200 
uL of SOC media was added to each 52 uL cell/DNA mix for a brief outgrowth period. The SOC 
media contained the following ingredients and then was sterilized and filtered: 0.5% yeast 
extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM 
Glucose. The cells in the media were put into a shaking incubator at 37°C for 2 hours, then 
plated (in various quantities) on LB plates (made with 1 mL Ampicillin at a concentration of 100 
mg/mL). These sat overnight in a 37°C incubator. Single colonies were picked for overnight 
cultures in 3 mL LB (w/Amp) each. These were mini-prepped using the Macherey-Nagel 
NucleoSpi Plasmid Mini Kit (Bethleme, PA) per the manufacturer’s instructions. The mini-prep 
products were run through a 1% agarose gel at room-temperature and 100 Volts, visualized by 
SYBR (from Qiagen), then cut out and gel-purified by Macherey-Nagel Gel and PCR Clean-Up 
Kit per the manufacturer’s instructions (Registry of Standard, n.d.). Verification gel(s) can be 
found in Figure 1 of the Appendix.  
 
Amplification of dCas9 and APOBEC 
dCas9: We amplified dCas9 DNA template (provided by the WPI 2016 iGEM team) via PCR 
reactions with Q5 master mix (New England BioLabs, Beverly, MA), using the following 
protocol:  
 
1x  [95 for 02:00] 
30x [95 for 00:30] 
 [59 for 00:45] 
 [72 for 04:30] 
1x  [72 for 10:00] 
Hold at 10 degrees for infinity 
 
The PCR product was run in a 1% agarose gel, visualized by SYBR (from Cambrex in Rockland, 
Maine), cut out and gel-purified by Qiagen purification kit. Verification gel(s) can be found in 
the Appendix. 
 
The temperature for annealing in the dCas9 amplification protocol was established by 
performing a gradient-temperature PCR reaction. We ran 12 identical reactions, each of 15 uL, 
spanning from 45 to 62 degrees Celsius. The brightest bands when visualized in an agarose gel 
by SYBR allowed us to calculate the optimal annealing temperature to be 59 degrees. For the gel 
results and calculation, please refer to Figure 2 of the Appendix section. 
 
APOBEC: We amplified APOBEC with 1Xten linker, 2Xten linker, and 3Xten linker (provided 
by the WPI 2016 iGEM team) via PCR reactions with Q5 master mix, using the following 
protocol: 
 
1x  [95 for 02:00] 
30x [95 for 00:30] 
 [55 for 00:45] 
 [72 for 01:00] 
1x  [72 for 10:00] 
 Hold at 10 degrees for infinity 
 
The PCR products were treated as described above. 
 
Cloning of dCas9 into pcDNA 
We used Gibson cloning method to attempt to clone dCas9 into our pcDNA3.1+ vector. We 
mixed 100 ng of gel-purified pcDNA3.1+ vector DNA with 200 ng of gel-purified dCas9 insert 
DNA, along 10 uL of NEBuilder HiFi DNA Assembly Master Mix and the remaining amount 
needed of deionized water to create a 20 uL total reaction. The reactions were incubated in a 
PCR machine for 30 minutes at 50°C. The reaction product was then transformed by mixing 2 
uL of the product into 50 uL of thawed competent DH5α e. coli cells (obtained by Professor 
Farny’s competent cell stock in the -80 degrees Celsius freezer), incubated on ice for 30 minutes, 
heat shocked at 42°C for 30 seconds, and put back on ice for 2 minutes. 950 uL of room 
temperature SOC media was added, the mix was then incubated at 37°C with vigorous shaking 
for 1 hour, then plated on prewarmed LB (w/Amp) plates, and incubated overnight at 37°C 
(Gibson, 2009 and New England BioLabs, n.d.). We further attempted to repeat this with un-gel-
purified dCas9 insert DNA, all the rest remaining the same. Our control for these reactions was 
to plate the plasmid without insert DNA, and cells without any transformation plasmid or insert 
DNA (Registry of Standard, n.d.). 
 
Transfection of dCas9/APOBEC Constructs 
For transfection, we followed the protocol found with TransFectin (from Bio-Rad), a highly 
efficient, lipid-based transfection reagent. We plated 600,000 cells into the wells of a 6-well 
plate and allowed 24 hours for adherence. We then added 2 µg of DNA with 10 µL TransFectin 
and counted this as time = 0 hours for imaging by microscopy. We performed two transfections 
using this basic process. 
 
The first transfection was conducted with H1299 cells, which is a human non-small cell lung 
carcinoma cell line, and was done as described above. The DNA inserted into the cells were the 
following constructs: APOBEC 1X, APOBEC 2X, APOBEC 3X, BE2, dCas9, and pRETRO. 
The control was cells with no DNA. The cells were incubated at a stable 37 degrees Celsius. 
After 48 hours, the cells were imaged (please see Results section).  
 
The second transfection was conducted with MCF7 cells, a breast cancer cell line, and was done 
as described above, with the following exception: the cells were incubated for 4 hours before 
changing media, completely removing the transfection reagent. The media used was standard 
DMEM, 10% FBS and 1% Pen-Strep (Gibco). The following three variations were the 
conditions used: transfection reagent and DNA, DNA only, and transfection reagent only. The 
DNA added for this transfection was the BE2 construct (Addgene Plasmid #73020). The control 
well contained only cells. All cells were imaged at 24 hours (please see Results section).   
 
 
  
RESULTS 
 
 
The first part of our project consisted of the re-cloning of dCas9 into the pcDNA3.1+ vector, to 
be followed by APOBEC with the 1X, 2X, and 3X size linkers. We first amplified our dCas9 
DNA through multiple PCR reactions, but rarely were able to produce enough DNA to begin 
molecular cloning. Because of this issue, we optimized the PCR protocol by performing a 
gradient-temperature PCR reaction in which the annealing temperature of the reaction was 
increased incrementally. Below, Figure 1 illustrates the results collected. 
 
 
Figure 3: Gradient-Temperature PCR Gel Results 
 
The lanes in the two gels sequentially represent reactions 1-12 of the temperature gradient, 
ranging from 45 to 62 degrees. The results shown in Figure 1 suggest an optimal annealing 
temperature between 57.78 (reaction 9) and 59.2 (reaction 10) degrees. Based on these results, 
the annealing temperature used in future PCRs was set to 59 degrees (full calculation can be 
found in Figure 2 of the Appendix). Using this modified PCR protocol, we continued amplifying 
the dCas9 DNA and began attempting to clone the DNA into pcDNA 3.1+ via Gibson assembly. 
 
Inserting the dCas9 DNA into the pcDNA 3.1+ vector proved difficult for unknown reasons. We 
believe that because of dCas9’s size (approximately 4.2 kb), the DNA was simply too big to 
successfully integrate into the pcDNA 3.1+ plasmid in one step. We suggest that in the future, 
the dCas9 gene could be split into two or three parts, amplified separately via PCR and inserted 
individually into the plasmid. By splitting the gene into parts, the size of the insert is 
dramatically reduced - possible making the cloning more successful.  
Because we had little time left in our MQP to complete the cloning process and transfect with 
our own constructs, we had the fortune to use iGEM’s previously made/purchased constructs for 
investigating transfection/expression of dCas9 and APOBEC in mammalian cells. We began by 
first taking each individual component of the pRETRO iGEM-constructs, as well as the 
AddGene plasmid BE2, and transfecting H1299 mammalian cells. The table below clarifies each 
of the DNA constructs we added to our transfection(s): 
 
Figure 4: Table of DNA Constructs Used in Transfection(s)  
 
DNA Construct Plasmid Backbone Contents Source 
“pRETRO” pRETRO none AddGene 
“dCas9” pRETRO dCas9 iGEM 
“APOBEC 1X” pRETRO APOBEC 1X iGEM 
“APOBEC 2X” pRETRO APOBEC 2X iGEM 
“APOBEC 3X” pRETRO APOBEC 3X iGEM 
“BE2” pCMV dCas9/APOBEC AddGene 
 
  
The following figure shows the images taken from the first transfection, which was done with 
H1299 cells: 
 
 
Figure 5: Cells 48 Hours Post-Transfection with Various Constructs Compared to Control 
 
 
From this transfection, we realized the incidence of massive cell death in every well except for 
the one that contained only cells (no transfection reagent and no DNA) - specifically, after 48 
hours, the cells with DNA added became suspended in the media, over 80% dead as compared to 
the anchored, 90% alive “cells only” well. This was an unexpected result, especially because a 
simple vector such as pRETRO should not theoretically cause cell death. Therefore, we wanted 
to determine which of the two added transfection ingredients (reagent or DNA) was the one 
responsible for killing the cells. To do this, we conducted a second experiment including proper 
controls to make a more thorough and substantiated conclusion. This second transfection 
involved transfecting MCF7 mammalian cells with only BE2. We decided to switch to the new 
cell type, MCF7, to determine if the cell type played any role in the results, and to prevent cell 
death if caused easily to the previous cell types tried (293T’s and H1299’s). 
 
The following figure shows the images taken from the second transfection, which was done with 
MCF7 cells: 
 
 
 
Figure 6: Cells 0 and 24 Hours Post-Transfection, Testing for Toxicity Cause 
 The images collected above indicate that the transfection reagent used (TransFectin) is 
responsible for the massive cell death observed in both Figures 2 and 3. This result could be due 
to a variety of reasons including: the age of the TransFectin (4+ years), or the plasmid itself. 
While the second column in Figure 3 indicates that the DNA is not killing the cells, the DNA is 
not able to enter the cells because of the absence of TransFectin, thus it would be useful to 
recapitulate these results with a Transfectin-only culture. This is important to note because once 
TransFectin is added, the DNA forms complexes with the TransFectin and enters the cells. BE2 
contains pRETRO as its plasmid backbone - a DNA sequence that originates from viruses. We 
suggest that cell death may be occurring in Figures 2 and 3 because of the use of pRETRO. As 
the DNA enters the cell, it may be integrating into the host genome and inducing apoptosis 
through either integrating in a non-optimal location (disrupting essential genes), or leading to 
interferon production in the cell which then leads to cellular apoptosis. We also recommend 
attempting the same transfections as above in media that does not contain antibiotic. While 
bacterial antibiotic, like Penn Strep, should not usually cause mammalian cell death, the increase 
in cell permeability via lipid-based transfection may be contributing to the observed cell death. 
Similarly, it is recommended that alternative transfection protocols be attempted, such as 
calcium-phosphate. 
DISCUSSION 
 
The foundational work completed by the iGEM team led to an exciting prospect for our MQP. It 
is indisputable that CRISPR technology offers boundless potential for applications ranging from 
medical to environmental. However, its technical concerns simultaneously present ethical 
concerns for the scientific community and the society at large. Firstly, accidental release of any 
genetically modified organism could lead to severe ecological disruptions. Any experimental 
organisms released into an ecosystem could quickly proliferate, spreading possibly hazardous 
DNA sequences throughout the ecosystem (Rodriguez 2016). A second, more economical 
concern, is the recent practice of patenting DNA sequences. CRISPR technology is frequently 
used to create and insert laboratory-produced DNA sequences that are then often used in 
applications for patents. This creates the ethical concern of whether it is morally right to patent 
genes or other DNA sequences (Rodriguez 2016). A final and most severe ethical concern 
associated with CRISPR is the practice of editing human genomes. Already, UNESCO has 
issued the Universal Declaration on the Human Genome and Human Rights which recommends 
a moratorium on human germline genome editing. Despite similar recommendations to avoid 
using tools like CRISPR on the human genome, some have argued the potential to treat a wide 
range of diseases, such as cystic fibrosis or sickle cell disease, through the tool (Rodriguez 
2016). It is these concerns that have placed CRISPR into a negative light in terms of public 
opinion and have founded the need for a safer, less controversial alternative to CRISPR. 
 
While we encountered obstacles in the lab that prevented us from progressing further in the 
development of this adapted CRISPR/Cas9 technology, we enjoyed the experience immensely 
and learned boundless skills in troubleshooting and critical thinking. We stress the importance of 
further developing this adapted CRISPR technology and highly encourage a future MQP team to 
pick up where we left off. To this end, we have compiled a list of major routes that we suggest 
such a team to proceed on. We look forward to the future development of this project. 
 
Our first major suggestion is the continued cloning of dCas9/APOBEC into the pcDNA3.1+ 
vector. Future persistence in these cloning aims should include APOBEC inserts of various size 
linkers into pcDNA3.1+, as well as into other standard and atypical vectors. Given the trouble we 
faced with cloning in dCas9, we propose splitting the dCas9 DNA into multiple parts and cloning 
them into the vector in pieces. Reducing the substantial size of the insert when cloning the DNA 
may facilitate uptake of the gene into a plasmid. 
 
Our second major suggestion is determining successful alternate transfection protocols to reduce 
toxicity to the cells. We suggest attempting the same transfection as done above, but in media 
that does not contain any antibiotic (our attempt at this yielded large contamination, making the 
cells difficult to image- we suggest trying several concentrations/quantities of antibiotic). We 
also suggest transfecting the cells using plasmids that do not originate from viruses in order to 
reduce possible interferon production post-transfection. Finally, we also suggest finding alternate 
methods of transfecting the DNA into the cells, in order to accurately determine the effect of the 
dCas9 construct(s), such as a calcium phosphate method. 
 
Once the dCas9/APOBEC construct(s) have successfully been cloned into an appropriate 
plasmid vector and the construct(s) have been transfected into mammalian cells, the next major 
step in the project can be continued. Firstly, one would need to verify the expression of the 
construct in vivo. Following that is to proceed with introducing guide RNA to target the 
CRISPR/Cas9 system for editing. Finally, conduction of RNA collection and sequencing, as well 
as protein analysis, would both be done to test for successful mRNA editing.   
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 APPENDIX 
 
Figure 1: Verification gels of pcDNA3.1+ and dCas9 
 
  
Lane 1 in both gels contains pcDNA3.1+ and Lane 2 in both gels contains amplified dCas9.  
 
 
Figure 2: Visualization Gels for Gradient-temperature Reactions in dCas9 PCR 
Protocol Optimization 
 
 
The temperature range over the 12 reactions was 45 to 62, spanning 17 degrees, each reaction 
representing a difference of 12/17=1.42 degrees. 
 
Reactions 8-11 are the most effective, evidenced by the brightest, cleanest, thickest bands.  
Therefore, Reaction 9 is 45+(9*1.42)=57.78 degrees. Reaction 10 is 45+(10*1.42)=59.2 degrees. 
Averaging the temperatures of reactions 9 and 10, we can conclude that the optimal temperature 
for the annealing step in our PCR protocol for dCas9 should be 58.49 or 58.5 degrees. 
 
The temperature we were using before performing this optimization was 55 degrees. 
 
 
Figure 3: Verification gel of dCas9 Amplification 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Vector Map of pcDNA3.1+ Plasmid (Addgene) 
 
 
 
 
Figure 5: Vector Map of BE2 Plasmid Construct (Addgene) 
 
 
 
Figure 6: Vector Map of pRETRO Plasmid (Addgene) 
 
 
 
 
